Steven Yatomi Clarke – CEO and Managing Director – Prescient Therapeutics (ASX:PTX) is a clinical-stage biotech company developing personalised medicine approaches to cancer, including targeted and cellular therapies.
Copyright 2023 – Finance News Network
Source: Finance News Network
06 Jan 2021 - Nyrada Limited (ASX:NYR) CEO James Bonnar discusses the cholesterol-lowering market, and recent results for the company's lead drug candidate, which achieved a 57% reduction in total cholesterol.
Read More29 Jul 2021 - BARD1 Life Sciences Limited (ASX:BD1) CEO Dr Leearne Hinch introduces the company, discussing its recent capital raising and share purchase plan.
Read More19 Nov 2019 - Redcape Hotel Group Limited (ASX:RDC) CEO, Dan Brady discusses FY19 results, company strategy and creating pub venues that become the hub of local communities.
Read More17 Nov 2023 - Findi Limited (ASX:FND) Chairman Nicholas Smedley discusses the details that its Indian subsidiary TSI has successfully raised $37.6m via a placement to leading Investment group, Piramal Alternatives.
Read More03 Feb 2021 - Novatti Group Limited (ASX:NOV) CEO Peter Cook provides an update on the company's record December quarter results, progress with strategic partners and overseas expansion plans.
Read More02 Jun 2023 - Falcon Metals Limited (ASX:FAL) Managing Director Tim Markwell discusses progress with the company's gold exploration, touching on key prospects and the results timeline.
Read More11 Mar 2021 - Rural Funds Group Limited (ASX:RFF) General Manager - Investor Relations and Marketing, James Powell, presents on the group's HY21 results.
Read More26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
Read More22 Nov 2021 - Arovella Therapeutics Limited (ASX:ALA) CEO & Managing Director Dr Michael Baker provides an update on the company's invariant Natural Killer T (iNKT) cell platform and its oral spray delivery technology to treat cancer and conditions that affect the central nervous system.
Read More16 Aug 2023 - Dr John Melki - CEO and Director - Genetic Signatures (ASX:GSS) is transforming molecular diagnostics via streamlined sample processing methods linked to highly multiplexed real-time PCR screening assays.
Read More
